BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 19533372)

  • 1. Fragment-based lead generation: identification of seed fragments by a highly efficient fragment screening technology.
    Neumann L; Ritscher A; Müller G; Hafenbradl D
    J Comput Aided Mol Des; 2009 Aug; 23(8):501-11. PubMed ID: 19533372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of fragment screening methods on the p38α kinase: new methods, new insights.
    Pollack SJ; Beyer KS; Lock C; Müller I; Sheppard D; Lipkin M; Hardick D; Blurton P; Leonard PM; Hubbard PA; Todd D; Richardson CM; Ahrens T; Baader M; Hafenbradl DO; Hilyard K; Bürli RW
    J Comput Aided Mol Des; 2011 Jul; 25(7):677-87. PubMed ID: 21732248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multiple roles of computational chemistry in fragment-based drug design.
    Law R; Barker O; Barker JJ; Hesterkamp T; Godemann R; Andersen O; Fryatt T; Courtney S; Hallett D; Whittaker M
    J Comput Aided Mol Des; 2009 Aug; 23(8):459-73. PubMed ID: 19533374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
    Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
    J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of compound libraries for fragment screening.
    Blomberg N; Cosgrove DA; Kenny PW; Kolmodin K
    J Comput Aided Mol Des; 2009 Aug; 23(8):513-25. PubMed ID: 19283339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.
    Hoffer L; Renaud JP; Horvath D
    J Chem Inf Model; 2013 Apr; 53(4):836-51. PubMed ID: 23537132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fragment based lead discovery of small molecule inhibitors for the EPHA4 receptor tyrosine kinase.
    van Linden OP; Farenc C; Zoutman WH; Hameetman L; Wijtmans M; Leurs R; Tensen CP; Siegal G; de Esch IJ
    Eur J Med Chem; 2012 Jan; 47(1):493-500. PubMed ID: 22137457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase.
    Smith CR; Dougan DR; Komandla M; Kanouni T; Knight B; Lawson JD; Sabat M; Taylor ER; Vu P; Wyrick C
    J Med Chem; 2015 Jul; 58(14):5437-44. PubMed ID: 26087137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and NMR validation of minimal pharmacophore hypotheses for the generation of fragment libraries enriched in heparanase inhibitors.
    Gozalbes R; Mosulén S; Carbajo RJ; Pineda-Lucena A
    J Comput Aided Mol Des; 2009 Aug; 23(8):555-69. PubMed ID: 19421720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CellFy: A Cell-Based Fragment Screen against C-Type Lectins.
    Schulze J; Baukmann H; Wawrzinek R; Fuchsberger FF; Specker E; Aretz J; Nazaré M; Rademacher C
    ACS Chem Biol; 2018 Dec; 13(12):3229-3235. PubMed ID: 30480432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The multi-copy simultaneous search methodology: a fundamental tool for structure-based drug design.
    Schubert CR; Stultz CM
    J Comput Aided Mol Des; 2009 Aug; 23(8):475-89. PubMed ID: 19506805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons for fragment library design: analysis of output from multiple screening campaigns.
    Chen IJ; Hubbard RE
    J Comput Aided Mol Des; 2009 Aug; 23(8):603-20. PubMed ID: 19495994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide.
    Kawatkar S; Wang H; Czerminski R; Joseph-McCarthy D
    J Comput Aided Mol Des; 2009 Aug; 23(8):527-39. PubMed ID: 19495993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase.
    Sullivan JE; Holdgate GA; Campbell D; Timms D; Gerhardt S; Breed J; Breeze AL; Bermingham A; Pauptit RA; Norman RA; Embrey KJ; Read J; VanScyoc WS; Ward WH
    Biochemistry; 2005 Dec; 44(50):16475-90. PubMed ID: 16342939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient search of chemical space: navigating from fragments to structurally diverse chemotypes.
    Wassermann AM; Kutchukian PS; Lounkine E; Luethi T; Hamon J; Bocker MT; Malik HA; Cowan-Jacob SW; Glick M
    J Med Chem; 2013 Nov; 56(21):8879-91. PubMed ID: 24117015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Energetic analysis of fragment docking and application to structure-based pharmacophore hypothesis generation.
    Loving K; Salam NK; Sherman W
    J Comput Aided Mol Des; 2009 Aug; 23(8):541-54. PubMed ID: 19421721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ligand specificity, privileged substructures and protein druggability from fragment-based screening.
    Barelier S; Krimm I
    Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.